Tesamorelin for abdominal fat: what does the research show?

Tesamorelin for abdominal fat has been extensively studied for its ability to reduce abdominal fat, particularly visceral adipose tissue, which is the deeply stored fat that accumulates around internal organs.

Tesamorelin has been extensively studied for its ability to reduce abdominal fat, particularly visceral abdominal fat, which is deep fat stored around internal organs. This type of fat is strongly associated with metabolic diseases, cardiovascular risk, insulin resistance, and fatty liver disease. Tesamorelin works by stimulating the body's natural production of growth hormone (GH) through the activation of growth hormone-releasing hormone (GHRH) receptors in the pituitary gland. As GH levels increase, the body also increases the production of insulin-like growth factor-1 (IGF-1), which supports lipolysis, the process of breaking down stored fat for energy production. Studies show that this process preferentially targets harmful visceral abdominal fat while preserving lean muscle mass and healthier subcutaneous fat located beneath the skin [1–4].

Clinical trials consistently show that tesamorelin significantly reduces visceral abdominal fat and improves overall body composition. In a placebo-controlled dose-ranging trial conducted by Falutz J et al. (2005), HIV-positive adults with excess abdominal fat who received tesamorelin experienced a significant reduction in visceral fat over 12 weeks [4]. Participants taking 2 mg daily achieved an approximate 15.71% reduction in visceral fat, along with a reduction in trunk fat, improved triglyceride levels, and an increase in lean body mass. Importantly, subcutaneous fat remained relatively stable, suggesting that tesamorelin selectively targets metabolically harmful abdominal fat rather than causing widespread fat loss throughout the body.

Similar results were observed in a study by Falutz J et al. (2007), which followed 412 HIV-positive adults with excess abdominal fat over a 26-week period [5]. Tesamorelin reduced visceral abdominal fat by approximately 15% compared with placebo, whilst improving triglyceride levels and the total cholesterol to HDL ratio. Participants also showed a measurable reduction in waist circumference and waist-to-hip ratio, indicating a visible improvement in abdominal obesity and body shape without a significant deterioration in glucose metabolism.

Long-term phase III studies have confirmed that tesamorelin can maintain a reduction in abdominal fat when treatment is continued. In a pooled multicentre analysis conducted by Falutz J et al. (2010), tesamorelin reduced visceral fat by approximately 15.4% among 806 HIV-positive participants receiving 2 mg daily [6]. The researchers also observed a significant reduction in waist circumference and an improvement in issues related to abdominal appearance and body image. Participants who continued treatment maintained the reduction in visceral fat for up to 52 weeks, whilst those who discontinued treatment regained abdominal fat relatively quickly. This finding suggests that continued stimulation of growth hormone pathways may be necessary to sustain the benefits.

Research also indicates that tesamorelin improves body composition beyond just reducing abdominal fat. Adrian S et al. (2019) demonstrated that individuals responding to tesamorelin treatment experienced an increase in muscle area and improved muscle density while simultaneously reducing abdominal fat [7]. Muscle density refers to the quality and composition of muscles, and these findings suggest that tesamorelin may support a healthier body composition while reducing harmful fat stores.

Tesamorelin has also been shown to have beneficial effects on hepatic fat, which is closely linked to abdominal obesity and metabolic disorders. In a randomised clinical trial by Stanley TL et al. (2014), tesamorelin significantly reduced both visceral abdominal fat and liver fat content in HIV-positive individuals with excess abdominal fat [8]. Fatty liver refers to the accumulation of fat within the liver. Further randomised studies on HIV-associated non-alcoholic fatty liver disease (NAFLD) showed that tesamorelin reduced hepatic fat by approximately 37% from baseline levels whilst simultaneously improving mitochondrial and metabolic pathways in the liver [9,10]. Mitochondria are the structures responsible for energy production in cells; therefore, these changes may reflect an improvement in the way the liver processes energy and fats.

Research also suggests that the reduction in abdominal fat achieved with tesamorelin may improve several markers of metabolic health. Stanley TL et al. (2012) demonstrated that individuals who achieved at least an 8% reduction in visceral fat also experienced lower triglyceride levels, increased adiponectin levels and stable glucose metabolism [11]. Adiponectin is a hormone produced by adipose tissue that helps improve insulin sensitivity and reduce inflammation associated with abdominal obesity.

Some individuals may experience a greater reduction in abdominal fat than others. Mangili A et al. (2015) demonstrated that participants with metabolic syndrome, obesity, elevated triglyceride levels, and higher cardiovascular risk factors achieved greater reductions in visceral fat during tesamorelin treatment [12]. Participants on tesamorelin were also significantly more likely to decrease their visceral fat levels below clinically relevant cardiovascular risk thresholds.

Research also shows that tesamorelin can consistently reduce abdominal fat regardless of different patterns of fat distribution. Rahman F et al. (2023) demonstrated that tesamorelin effectively reduced visceral fat in HIV-positive individuals, both with and without the accumulation of fat in the neck area, often referred to as a „buffalo hump” [13]. Participants in both groups experienced similar reductions in visceral adipose tissue and waist circumference, suggesting that tesamorelin targets deep abdominal fat regardless of how fat is distributed in other areas of the body.

Generally speaking, current research indicates that tesamorelin effectively reduces abdominal fat by stimulating natural GH and IGF-1 production via physiological GHRH signalling pathways. Clinical studies consistently demonstrate reductions in visceral abdominal fat, decreases in waist circumference, favourable changes in body composition, preservation of lean muscle mass, reduction in liver fat, and improvements in metabolic health markers. Importantly, these effects appear to be primarily concentrated on metabolically unhealthy visceral fat, rather than overall weight loss [4–13].

Tesamorelin used in laboratory research is available from suppliers such as SemaxPolska. Please note that research findings refer to controlled scientific conditions and do not constitute confirmation of clinical efficacy in other applications.

Disclaimer

The content is for educational and scientific information purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is a prescription medication, primarily approved for the treatment of HIV-associated lipodystrophy. Therapies affecting growth hormone and metabolic pathways require medical supervision, laboratory monitoring, and individual clinical assessment by a qualified healthcare professional.